Eli Lilly raised full-year revenue guidance to $91 billion to $92 billion, up $5.5 billion at the midpoint from prior guidance of $85 billion to $87 billion. The stock trades at 47 times trailing earnings, more than double the pharmaceutical industry average, but the catalyst pipeline suggests the multiple has room to expand.
Third-quarter revenue reached $24.4 billion, up 39 percent year-over-year, with earnings per share rising 16 percent to $7.22. Mounjaro (tirzepatide for type 2 diabetes) and Zepbound (tirzepatide for obesity) drove the outperformance. Zepbound sales climbed 49 percent to $5.4 billion; Mounjaro jumped 65 percent to $10.7 billion. Lilly's oral weight-loss drug Foundayo contributed $184 million.
Tirzepatide became the world's best-selling drug last year, surpassing Merck's Keytruda. That shift matters because it signals a market repricing around obesity treatment as a primary indication rather than a secondary use case.
Morgan Stanley projects the global obesity drug market will reach $190 billion by 2035, more than double the 2025 forecast. The Street's math hinges on two drivers: faster adoption of oral formulations over injectables and Medicare coverage expansion in the U.S. But both assumptions look conservative against on-the-ground adoption trends.
The bigger upside lies offshore. Morgan Stanley estimates 1 billion people with obesity live outside the United States, with Europe representing the only meaningfully penetrated market today. Brazil and China present the next growth frontiers, constrained today by affordability, needle aversion, and local regulatory hurdles—all addressable problems as Lilly scales manufacturing and as governments expand reimbursement.
Beyond obesity, GLP-1 drugs are proving efficacy across cardiovascular, kidney, liver, arthritis, and sleep apnea indications. The National Institutes of Health has documented these benefits, attributable to anti-inflammatory and metabolic pathways. A Washington University study found GLP-1 drugs associated with reduced risk of substance use disorders and lower rates of overdose death in affected populations—a signal that could expand the addressable market into addiction medicine if clinical trials confirm causation.
Eli Lilly's revenue growth acceleration, combined with geographic expansion potential and emerging therapeutic applications, supports higher Street price targets. At current levels, the risk/reward tilts toward upside for long-term holders who can stomach near-term volatility.
